Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.30 – $0.30
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $8.2M | $14.4M | $8.6M | $5.2M | $6.9M | $7.9M | $16.8M |
| Cost of revenue | $826.7K | $0 | $1.5M | $1.4M | $18.1M | $18.4M | $1.1M | $10.2M |
| Gross profit | $3.9M | $5.8M | $12.9M | $7.2M | −$12.9M | −$11.5M | $6.7M | $6.5M |
| Gross margin | 82.5% | 71.1% | 89.5% | 84.3% | -245.3% | -166.6% | 85.9% | 39.0% |
| R&D | $16.3M | $17.7M | $12.7M | $17.9M | $18.0M | $7.6M | $6.0M | $0 |
| Operating income | −$21.8M | −$19.0M | −$6.8M | −$18.2M | −$29.4M | −$17.1M | −$9.9M | $3.2M |
| EBITDA | −$21.7M | −$18.0M | −$14.1M | −$16.0M | −$21.4M | −$19.7M | −$20.6M | $3.2M |
| Net income | −$18.4M | −$18.9M | −$18.1M | −$43.8M | −$31.3M | −$20.9M | −$22.4M | −$2.4M |
| Net margin | -389.9% | -231.7% | -125.5% | -509.9% | -596.8% | -302.5% | -284.9% | -14.4% |
| EPS (diluted) | -0.62 | -0.56 | -0.54 | -1.17 | -0.62 | -0.42 | -0.45 | -0.03 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $0.01 | $0.01–$0.01 | 1 |
| 2027 | $20M | $0.12 | $0.12–$0.12 | 1 |
Forward consensus · source: Financial Modeling Prep
NICOX SA EUR ORD NEW
No one on the platform currently holds NICXF.
No tracked institution reports a position in NICXF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2015-12-08 | 1-for-5reverse |
No one on the platform has traded NICXF yet.
| $131M |
| — |
| IUGNFImugene Limited | $0.08 | -20.00% | $33M | — |
| PHYOFIXICO plc | $0.07 | +0.00% | $7M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.